Blood interleukin 10 levels parallel the severity of septic shock.
暂无分享,去创建一个
[1] J. Reynolds,et al. Interleukin-10. A role in the development of postoperative immunosuppression. , 1997 .
[2] P. Parsons,et al. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. , 1997, American journal of respiratory and critical care medicine.
[3] T. van der Poll,et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. , 1997, Journal of immunology.
[4] S. Ashley,et al. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. , 1996, Surgery.
[5] A. J. van der Heijden,et al. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. , 1996, The Journal of infectious diseases.
[6] T. van der Poll,et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.
[7] E. Radwanski,et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. , 1996, Blood.
[8] J. Vincent,et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. , 1996, Surgery.
[9] U. Steckholzer,et al. Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia. , 1996, Archives of surgery.
[10] T. van der Poll,et al. Endogenous IL-10 protects mice from death during septic peritonitis. , 1995, Journal of immunology.
[11] T. Standiford,et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. , 1995, Journal of immunology.
[12] A. Eerenberg,et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. , 1995, The Journal of infectious diseases.
[13] A. Waage,et al. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease , 1995, Infection and immunity.
[14] L. Shapiro,et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.
[15] X. Nuvials,et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. , 1995, The Journal of infectious diseases.
[16] M. Goldman,et al. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. , 1995, The Journal of infectious diseases.
[17] T. van der Poll,et al. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees , 1994, The Journal of experimental medicine.
[18] P. Quirke,et al. Role of circumferential margin involvement in the local recurrence of rectal cancer , 1994, The Lancet.
[19] P. Vandenabeele,et al. Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.
[20] J. Cavaillon,et al. Circulating interleukin‐8 concentrations in patients with multiple organ failure of septic and nonseptic origin , 1994, Critical care medicine.
[21] J. Devière,et al. Interleukin-10 production during septicaemia , 1994, The Lancet.
[22] C. Wanidworanun,et al. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. , 1993, Journal of immunology.
[23] G. Constantin,et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide , 1993, The Journal of experimental medicine.
[24] T. van der Poll,et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. , 1993, The Journal of infectious diseases.
[25] M. Howard,et al. Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.
[26] J. Vincent,et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.
[27] W. Fiers,et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.
[28] S. Moncada,et al. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. , 1992, Biochemical and biophysical research communications.
[29] T. Mosmann,et al. IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.
[30] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.
[31] T. Calandra,et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.
[32] H. Büller,et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .
[33] C. Hack,et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. , 1989, The American journal of medicine.
[34] C. Sprung,et al. Complement activation in septic shock patients , 1986, Critical care medicine.
[35] Germaine Greer,et al. van Deventer H , 1968 .